Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva

Executive Summary

Part two of Scrip's preview of first quarter earnings: Recent launches, pricing strategies and biosimilar competition will be key themes as top-tier pharmaceutical companies continue to report first quarter performance.

Advertisement

Related Content

Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer
Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump
Finally! Shire And Baxalta Sign $32bn Deal To Form Largest Rare Disease Company

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098616

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel